Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Oncogene is Scopus-indexed (Q1, CiteScore 14), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Nature.
Checked against the index lists dated .
ISSN 0950-9232Verify ISSN ↗1476-5594Verify ISSN ↗
Publisher: Springer Nature
Cost to publish: About US$5,990 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics | 17 / 357 | 95th | Q1 |
| Molecular Biology | 36 / 414 | 91st | Q1 |
| Cancer Research | 26 / 233 | 89th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1987–present, best quartile Q1, CiteScore 14.
Oncogene is Q1 in Genetics (rank 17 of 357), Q1 in Molecular Biology (rank 36 of 414) and Q1 in Cancer Research (rank 26 of 233), by CiteScore 2025.
Oncogene is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 14, which places it in quartile Q1 at the 95th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.474, quartile Q1, with an H-index of 387.
The publisher lists an article processing charge of about US$5,990 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Oncogene is published by Springer Nature. Its print ISSN is 0950-9232 and its online ISSN is 1476-5594.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Oncogene has an h-index of 426 and a 2-year mean of 6.45 citations per paper (OpenAlex). Its Scopus CiteScore is 14, quartile Q1. On 2-year citations it ranks #33 of 353 Scopus journals in Genetics.
Oncogene published 403 papers in 2025; its busiest recent year was 2018 with 573. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from China (61.6%), United States (18.5%) and Japan (4.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 163 retracted papers are recorded (8.3 per 1,000 papers). The Problematic Paper Screener flags 6 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.